Dendrion Epitel 1, LLC is a venture capital fund based in Chicago, Illinois. According to its most recent Form D, filed Jun 15, 2026, it has sold $1,255,000 of interests to 32 investors since its first sale in May 2026. The filing does not set a minimum investment. It relies on the Section 3(c)(1) exclusion, which limits it to 100 beneficial owners, typically accredited investors. The offering uses Rule 506(b), which does not permit general solicitation. Based on its first sale date and the amount raised, AltMountain classifies it as an emerging manager. Related persons named in the filing include Tyler Wanke.
- Total raised
- $1,255,000Cumulative sales reported on Form D
- Investors
- 32
- First sale
- May 29, 2026
- Minimum investment
- None set
- Who can invest
- Accredited investorsSection 3(c)(1): up to 100 beneficial owners
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Tyler Wanke
- Latest Form D
- Jun 15, 2026
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about Dendrion Epitel 1, LLC
What is the minimum investment for Dendrion Epitel 1, LLC?
Dendrion Epitel 1, LLC's latest Form D, filed Jun 15, 2026, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in Dendrion Epitel 1, LLC?
Dendrion Epitel 1, LLC is generally open only to accredited investors, and it may have no more than 100 beneficial owners because it relies on Section 3(c)(1). It uses Rule 506(b), which does not allow general advertising.
How much has Dendrion Epitel 1, LLC raised?
Dendrion Epitel 1, LLC reports $1,255,000 sold from 32 investors on its Form D filed Jun 15, 2026. This is cumulative sales since the offering began, not current assets or performance.
Where is Dendrion Epitel 1, LLC based?
Dendrion Epitel 1, LLC is based in Chicago, Illinois.
When did Dendrion Epitel 1, LLC launch?
Dendrion Epitel 1, LLC reports its first sale in May 2026, which makes it an emerging manager by AltMountain's definition (first sale in 2021 or later and under $50 million raised).
Size compared with every venture capital fund
Raised more than 43% of the 148 venture capital funds based in Illinois, and more than 65% of all 15,160 that report sales.